New Introduction Strategies in Asia/US to Generate Awareness of CGM importance
LAWRENCE, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Following the extension of the licensing and distribution agreement with Asian based partner, Advance Pharmaceutical Company Limited (APC), a registered formulation, marketed as a food supplement under the name SUGARBALANCE is currently available in Korea. This significant shipment marks a start to the sales of SUGARBALANCE in the territory.
According to Carl W Rausch, CEO, the adoption of a safe, novel treatment for sugar excesses sets the stage for the introduction of SUGARDOWN® (SUGARBLOCK, SUGARBALANCE in other Asia Pacific markets) in this growing market. “This shipment marks the introduction of an innovative regimen to the treatment and management of post prandial blood sugar elevations and the immediate intervention that delay disease related metabolic syndromes.” Backed by clinical evidence obtained in recently completed trial (https://clinicaltrials.gov/ct2/show/NCT02358668), APC is confident in their ability to make an impact on health economics in this country and the other 12 countries in which they are positioned to penetrate.
The company anticipates growing sales performance as the awareness of CGM (continuous glucose monitoring devices, Abbott, Medtronic, Dexcom) continue to establish educational material of this important blood glucose measure. We intend to address this in local languages and foster distribution channels in these underserved populations. According to the Korean Diabetes association, 6.6 million people in Korea are affected by diabetes and prediabetes. This indicates that 1 in every 5 Koreans are affected with the metabolic disease (http://pulsenews.co.kr/view.php?year=2017&no=216297). SUGARDOWN®, SUGARBALANCE, is the type of healthy lifestyle management aid that we believe can have a major impact on disease progression and may become an important part of a pre-diabetes regimen as shown by data presented earlier this year at the 77th ADA conference.
About Boston Therapeutics, Inc. www.bostonti.com
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) is an innovator in design, development and commercialization of compounds, such as BTI-320, to treat diabetes and diabetes related complications. SUGARDOWN® is a registered trademark of Boston Therapeutics, Inc.
Forward Looking Statement
This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.